StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Free Report) in a research report released on Thursday morning. The firm issued a sell rating on the stock.
Ayala Pharmaceuticals Trading Up 4.6 %
Ayala Pharmaceuticals stock opened at $0.56 on Thursday. The company’s 50-day moving average price is $0.67 and its two-hundred day moving average price is $0.72. The stock has a market cap of $5.97 million, a price-to-earnings ratio of -0.07 and a beta of 1.63. Ayala Pharmaceuticals has a 52 week low of $0.50 and a 52 week high of $1.95.
Ayala Pharmaceuticals (NASDAQ:ADXS – Get Free Report) last issued its quarterly earnings results on Tuesday, April 16th. The company reported ($2.96) earnings per share (EPS) for the quarter.
About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.
Recommended Stories
- Five stocks we like better than Ayala Pharmaceuticals
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- MarketBeat Week in Review – 4/29 – 5/3
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- What Is WallStreetBets and What Stocks Are They Targeting?
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
